ImageneBio (IMA) Insider Trading & Ownership $14.67 -0.03 (-0.20%) As of 08/8/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ImageneBio (NASDAQ:IMA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.94%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$10.50MNumber OfInsiders Selling(Last 12 Months)0 Get IMA Insider Trade Alerts Want to know when executives and insiders are buying or selling ImageneBio stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address IMA Insider Buying and Selling by Quarter ImageneBio Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/25/2025David P BonitaDirectorBuy83,611$29.90$2,499,968.90 7/25/2025Otello StampacchiaDirectorBuy267,556$29.90$7,999,924.40 (Data available from 1/1/2013 forward) IMA Insider Trading Activity - Frequently Asked Questions Who is on ImageneBio's Insider Roster? The list of insiders at ImageneBio includes David P Bonita, and Otello Stampacchia. Learn more on insiders at IMA. What percentage of ImageneBio stock is owned by insiders? 5.94% of ImageneBio stock is owned by insiders. Learn more on IMA's insider holdings. Which ImageneBio insiders have been buying company stock? The following insiders have purchased IMA shares in the last 24 months: David P Bonita ($2,499,968.90), and Otello Stampacchia ($7,999,924.40). How much insider buying is happening at ImageneBio? Insiders have purchased a total of 351,167 IMA shares in the last 24 months for a total of $10,499,893.30 bought. ImageneBio Key ExecutivesDr. Mark Manfredi Ph.D. (Age 53)President, CEO & Director Compensation: $810.69kDr. Jotin Marango M.D. (Age 45)Ph.D., CFO & Head of Corporate Development Compensation: $577.12kMr. Bob LallySenior Vice President of Finance & OperationsMs. Srividya Subramanian Esq.Ph.D., VP & Deputy General CounselMs. Samantha VuksanicHead of Human ResourcesMr. Jeffrey Ecsedy Ph.D. (Age 54)Chief Development Officer Mr. Navin Parwani M.S.VP & Head of QualityMr. David Damphousse M.S.Senior Vice President of Clinical Development OperationsDr. Caroline Germa M.D. (Age 52)Ph.D., Chief Medical Officer Mr. Valdas Jurkauskas Ph.D.Senior Vice President of Technical Operations More Insider Trading Tools from MarketBeat Related Companies DRUG Insider Buying CLDI Insider Buying MNPR Insider Buying ALLO Insider Buying DSGN Insider Buying GALT Insider Buying ALMS Insider Buying TKNO Insider Buying BTMD Insider Buying FENC Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:IMA) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
